Cargando…
Profile of vismodegib and its potential in the treatment of advanced basal cell carcinoma
Basal cell carcinoma (BCC) is the most common human malignancy. Recent advances in our understanding of the critical biologic pathways implicated in the development and progression of BCC have led to the development of the first molecular targeted therapy for this disease. The hedgehog pathway is mu...
Autores principales: | Macha, Muzafar A, Batra, Surinder K, Ganti, Apar Kishor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3736971/ https://www.ncbi.nlm.nih.gov/pubmed/23940421 http://dx.doi.org/10.2147/CMAR.S45976 |
Ejemplares similares
-
Treatment of Locally Advanced Basal Cell Carcinomas with Vismodegib
por: Mastronardi, Luis, et al.
Publicado: (2021) -
Vismodegib in Locally Advanced Basal Cell Carcinoma in Slovenia
por: Mesti, Tanja, et al.
Publicado: (2022) -
Vismodegib: A smoothened inhibitor for the treatment of advanced basal cell carcinoma
por: Aditya, Suruchi, et al.
Publicado: (2013) -
Vismodegib treatment in advanced basal cell carcinomas: Real‐life experience
por: Villani, Alessia, et al.
Publicado: (2021) -
Targeted Therapy for Advanced Basal-Cell Carcinoma: Vismodegib and Beyond
por: Cowey, C. Lance
Publicado: (2013)